# Envista Holdings Corp (NVST)

> Cited company facts from SEC filings, by Steadybase. Web page: https://steadybase.io/company/envista-holdings-corp/ JSON: https://steadybase.io/company/envista-holdings-corp.json Checked Nov 10, 2026. Latest filing read: Nov 4, 2026.

## Company

- Legal name: Envista Holdings Corp
- Ticker: NVST (NYSE)
- SEC CIK: 0001757073
- Industry: Dental Equipment & Supplies (SIC 3843)
- Headquarters: Brea, CA
- Fiscal year ends: December 31
- SEC filer category: Large accelerated filer
- Website: envistaco.com
- LinkedIn: https://www.linkedin.com/company/envista-co
- Next earnings date: Feb 3, 2027 (estimated from past 8-K timing)

## Key facts

- Revenue: $2.7B for the fiscal year ended Dec 31, 2025 (10-K filed Feb 12, 2026). Source: https://www.sec.gov/Archives/edgar/data/1757073/000175707326000011/0001757073-26-000011-index.html
- Operating income: $216.1M for the fiscal year ended Dec 31, 2025 (10-K filed Feb 12, 2026). Source: https://www.sec.gov/Archives/edgar/data/1757073/000175707326000011/0001757073-26-000011-index.html
- Net income: $47.0M for the fiscal year ended Dec 31, 2025 (10-K filed Feb 12, 2026). Source: https://www.sec.gov/Archives/edgar/data/1757073/000175707326000011/0001757073-26-000011-index.html
- SG&A: $1.2B for the fiscal year ended Dec 31, 2025 (10-K filed Feb 12, 2026). Source: https://www.sec.gov/Archives/edgar/data/1757073/000175707326000011/0001757073-26-000011-index.html
- Employees: 12,000 as of Dec 31, 2025, as reported in an SEC filing. Source: https://www.sec.gov/Archives/edgar/data/1757073/000175707326000011/nvst-20251231.htm
- Shares outstanding: 160,344,938 as of Oct 30, 2026 (10-Q filed Nov 4, 2026). Source: https://www.sec.gov/Archives/edgar/data/1757073/000175707326000087/0001757073-26-000087-index.html
- Auditor: Ernst & Young LLP, Irvine, California, named in the latest 10-K. Source: https://www.sec.gov/Archives/edgar/data/1757073/000175707326000011/nvst-20251231.htm

## Business

Envista is a global family of more than 30 trusted dental brands, including Nobel Biocare, Ormco, DEXIS, and Kerr, united by a shared purpose: to partner with professionals to improve lives. We help our customers deliver the best possible patient care through industry-leading products, solutions, and technology. Our comprehensive portfolio, including dental implants and treatment options, orthodontics, and digital imaging technologies, covers a wide range of dentists' clinical needs for diagnosing, treating, and preventing dental conditions as well as improving the human smile.

Source: Item 1. Business, https://www.sec.gov/Archives/edgar/data/1757073/000175707326000011/nvst-20251231.htm

## Annual results

| Fiscal year ended | Revenue | Operating income | Net income | SG&A |
|---|---|---|---|---|
| Dec 31, 2025 | $2.7B | $216.1M | $47.0M | $1.2B |
| Dec 31, 2024 | $2.5B | -$1.0B | -$1.1B | $1.2B |
| Dec 31, 2023 | $2.6B | $31.5M | -$100.2M | $1.1B |
| Dec 31, 2022 | $2.6B | $319.2M | $243.1M | $1.1B |
| Dec 31, 2021 | $2.5B | $306.2M | $340.5M | $1.0B |

Each figure comes from the annual report for that year. Filing links for every figure: https://steadybase.io/company/envista-holdings-corp.json

## Officers and directors

- Paul Keel, CEO. LinkedIn: https://linkedin.com/in/paul-keel. Source: 8-K filed Nov 4, 2026, https://www.sec.gov/Archives/edgar/data/1757073/000175707326000085/nvst-ex991x10226xworkingfi.htm
- Paul A. Keel, Chairman and CEO. Source: Form 4 filed Aug 20, 2026, https://www.sec.gov/Archives/edgar/data/1757073/000162633726000010/0001626337-26-000010-index.htm
- Eric D. Hammes, Chief Financial Officer. Source: Form 4 filed Aug 27, 2026, https://www.sec.gov/Archives/edgar/data/1757073/000161049326000009/0001610493-26-000009-index.htm
- Eric Hammes, Chief Financial Officer. LinkedIn: https://www.linkedin.com/in/eric-hammes-30711693. Source: 8-K filed Aug 19, 2026, https://www.sec.gov/Archives/edgar/data/1757073/000175707326000074/nvst-20260817.htm
- Robert Befidi, President, Diagnostics. LinkedIn: https://linkedin.com/in/robertbefidijr. Source: Form 4 filed Aug 27, 2026, https://www.sec.gov/Archives/edgar/data/1757073/000201236126000007/0002012361-26-000007-index.htm
- Stefan Nilsson, President, Nobel Biocare. Source: Form 4 filed Aug 27, 2026, https://www.sec.gov/Archives/edgar/data/1757073/000204581826000005/0002045818-26-000005-index.htm
- Veronica Acurio, President, Orthodontics. Source: Form 4 filed Aug 27, 2026, https://www.sec.gov/Archives/edgar/data/1757073/000204584626000007/0002045846-26-000007-index.htm
- Coree Thomas, Vice President and Chief Accounting Officer. LinkedIn: https://linkedin.com/in/coree-thomas-0204687. Source: 8-K filed Jun 3, 2026, https://www.sec.gov/Archives/edgar/data/1757073/000175707326000051/nvst-20260528.htm
- Faez C. Kaabi, Chief Accounting Officer. Source: Form 4 filed Feb 27, 2026, https://www.sec.gov/Archives/edgar/data/1757073/000199352826000003/0001993528-26-000003-index.htm
- Mark E. Nance, General Counsel. LinkedIn: https://linkedin.com/in/mark-nance-b4b7. Source: Form 4 filed Feb 27, 2026, https://www.sec.gov/Archives/edgar/data/1757073/000175588226000004/0001755882-26-000004-index.htm
- Mischa Reis, SVP, Strategy & Bus. Dev.. Source: Form 4 filed Aug 24, 2026, https://www.sec.gov/Archives/edgar/data/1757073/000178863226000009/0001788632-26-000009-index.htm
- Coree K. Thomas, CAO. Source: Form 3 filed Aug 13, 2026, https://www.sec.gov/Archives/edgar/data/1757073/000214924826000003/0002149248-26-000003-index.htm
- Mischa M. Reis, Named in proxy. LinkedIn: https://linkedin.com/in/mischareis. Source: DEF 14A filed Apr 7, 2026, https://www.sec.gov/Archives/edgar/data/1757073/000175707326000031/nvst-20260406.htm

## Recent 8-K events

- Nov 4, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 7.01, Regulation FD disclosure; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1757073/000175707326000085/nvst-20261104.htm
- Oct 27, 2026: Item 7.01, Regulation FD disclosure; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1757073/000175707326000080/nvst-20261027.htm
- Sep 17, 2026: Item 7.01, Regulation FD disclosure. Source: https://www.sec.gov/Archives/edgar/data/1757073/000175707326000078/nvst-20260917.htm
- Aug 19, 2026: Item 5.02, Departure or appointment of directors or officers; compensation; Item 8.01, Other events; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1757073/000175707326000074/nvst-20260817.htm
- Aug 5, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 7.01, Regulation FD disclosure; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1757073/000175707326000063/nvst-20260805.htm
- Jun 3, 2026: Item 5.02, Departure or appointment of directors or officers; compensation; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1757073/000175707326000051/nvst-20260528.htm
- May 21, 2026: Item 5.07, Submission of matters to a vote of security holders; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1757073/000175707326000043/nvst-20260519.htm
- May 6, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 7.01, Regulation FD disclosure; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1757073/000175707326000040/nvst-20260506.htm
- Feb 5, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 7.01, Regulation FD disclosure; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1757073/000175707326000005/nvst-20260205.htm
- Oct 29, 2025: Item 2.02, Results of operations and financial condition (earnings release); Item 7.01, Regulation FD disclosure; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1757073/000175707325000055/nvst-20251029.htm

## Insider trades (Form 4)

- Aug 20, 2026: Mischa Reis (SVP, Strategy & Bus. Dev.) sold 8,000 shares, about $220,000. Source: https://www.sec.gov/Archives/edgar/data/1757073/000178863226000009/0001788632-26-000009-index.htm
- Feb 10, 2026: Mischa Reis (SVP, Strategy & Bus. Dev.) sold 9,675 shares, about $290,250. Source: https://www.sec.gov/Archives/edgar/data/1757073/000178863226000004/0001788632-26-000004-index.htm
- Aug 25, 2025: Mischa Reis (SVP, Strategy & Bus. Dev.) sold 15,000 shares, about $324,000. Source: https://www.sec.gov/Archives/edgar/data/1757073/000178863225000003/0001788632-25-000003-index.htm

## What management said

- "Envista delivered another quarter of profitable growth, gaining share and expanding margins" Paul Keel, CEO (8-K filed Nov 4, 2026). Source: https://www.sec.gov/Archives/edgar/data/1757073/000175707326000085/nvst-ex991x10226xworkingfi.htm

## Latest filings

- 8-K filed Oct 27, 2026: https://www.sec.gov/Archives/edgar/data/1757073/000175707326000080/nvst-20261027.htm
- 10-K filed Feb 12, 2026: https://www.sec.gov/Archives/edgar/data/1757073/000175707326000011/nvst-20251231.htm
- 10-Q filed Aug 5, 2026: https://www.sec.gov/Archives/edgar/data/1757073/000175707326000066/nvst-20260703.htm
- DEF 14A filed Apr 7, 2026: https://www.sec.gov/Archives/edgar/data/1757073/000175707326000031/nvst-20260406.htm

## About this data

SEC EDGAR filings, read by Steadybase. Every value links to the filing it came from.
Steadybase covers US-headquartered public companies that file with the SEC. API and MCP access: https://steadybase.io/docs/